Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2019
Price : $35 *
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions
- Acronyms OPTIVISMO-1
- 09 Jan 2019 Planned End Date changed from 1 Jul 2020 to 1 Aug 2020.
- 09 Jan 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Aug 2020.
- 09 Jan 2019 Status changed from not yet recruiting to recruiting.